However, being significantly overweight or obese can increase the risk of conditions such as heart disease, diabetes, and joint problems at any age
It is shorter acting and more relevant to research models focused on transient GHRH receptor activation
My Dopamine Experience (00:36:58) Tool 3 Controlling Dopamine Peaks & Baselines (00:40:06) Chocolate, Sex (Pursuit & Behavior), Nicotine, Cocaine, Amphetamine, Exercise (00:46:46) Tool 4 Caffeine Increases Dopamine Receptors (00:49:54) Pursuit, Excitement & Your Dopamine Setpoint (00:56:46) Your Pleasure-Pain Balance & Defining Pain (01:00:00) Addiction, Dopamine Depletion, & Replenishing Dopamine (01:07:50) Tool 5 Ensure Your Best (Healthy) Dopamine Release (01:15:28) Smart Phones: How They Alter Our Dopamine Circuits (01:19:45) Stimulants & Spiking Dopamine: Counterproductive for Work, Exercise & Attention (01:22:20) Caffeine Sources Matter: Yerba Mate & Dopamine Neuron Protection (01:24:20) Caffeine & Neurotoxicity of MDMA (01:26:15) Amphetamine, Cocaine & Detrimental Rewiring of Dopamine Circuits (01:27:57) Ritalin, Adderall, (Ar)Modafinil: ADHD versus non-Prescription Uses (01:28:45) Tool 6 Stimulating Long-Lasting Increases in Baseline Dopamine (01:37:55) Tool 7 Tuning Your Dopamine for Ongoing Motivation (01:47:40) Tool 8 Intermittent Fasting: Effects on Dopamine (01:53:09) Validation of Your Pre-Existing Beliefs Increases Dopamine (01:53:50) Tool 9 Quitting Sugar & Highly Palatable Foods: 48 Hours (01:55:36) Pornography (01:56:50) Wellbutrin & Depression & Anxiety (01:58:30) Tool 10 Mucuna Pruriens, Prolactin, Sperm, Crash Warning (02:01:45) Tool 11 L-Tyrosine: Dosages, Duration of Effects & Specificity (02:05:20) Tool 12 Avoiding Melatonin Supplementation, & Avoiding Light 10pm-4am (02:07:00) Tool 13 Phenylethylamine (with Alpha-GPC) For Dopamine Focus/Energy (02:08:20) Tool 14 Huperzine A (02:10:02) Social Connections, Oxytocin & Dopamine Release (02:12:20) Direct & Indirect Effects: e.g., Maca
In addition, it is recommended that the duration of future clinical trials of GLP-1RAs for AD extend to 2 to 3 years to evaluate long-term outcomes, including changes in cognition, activities of daily living, instrumental activities of daily living, and biomarkers for tau and A
Why wraparound solutions matter Medication alone was never meant to carry the full burden of obesity treatment
Alcohol Can weaken the LES and increase acid production
